11 03, 2026

TAmiRNA @ RNA Leaders Europe Conference

2026-03-11T10:10:00+01:00March 11th, 2026|biomarker, circulating miRNAs, Conference, microRNA, microRNA services, NGS, RNA|Comments Off on TAmiRNA @ RNA Leaders Europe Conference

Vienna, Austria – 17.-19. March 2026 TAmiRNA is pleased to announce that CEO/CSO Matthias Hackl and Head of R&D Teresa Krammer will attend the upcoming RNA Leaders Europe Conference, one of the leading industry events dedicated to RNA therapeutics, innovation, and translational research. RNA Leaders Europe brings together key stakeholders from academia, biotech, pharma, and technology providers to discuss the latest scientific advances, regulatory developments, and commercialization strategies in the rapidly evolving RNA field. As a specialized provider of RNA-focused services, TAmiRNA supports partners worldwide with comprehensive solutions ranging from RNA profiling and biomarker discovery to advanced bioinformatics and customized data analysis. The conference offers an excellent platform to exchange insights, explore collaborations, and discuss how cutting-edge [...]

2 03, 2026

Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

2026-03-02T10:12:31+01:00March 2nd, 2026|biomarker, circulating miRNAs, Illumina NewSeq2000, microRNA, microRNA services, NGS, T1D, Type 1 Diabetes|Comments Off on Independent Validation of Circulating microRNAs as Biomarkers in Type 1 Diabetes

TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D). The study, published in PLOS ONE (2026), strengthens growing evidence that circulating microRNAs serve as minimally invasive biomarkers with potential applications in disease monitoring and precision medicine. Study Overview: microRNA Biomarkers in Adolescent Type 1 Diabetes Reliable biomarkers are essential for improving disease monitoring and long-term management of type 1 diabetes. MicroRNAs — small, non-coding RNA molecules regulating gene expression — are detectable in blood and have emerged as promising non-invasive diagnostic and prognostic tools. This case-control study investigated previously reported circulating miRNAs in: 24 adolescents with type [...]

7 01, 2026

TAmiRNA Research on microRNA Biomarkers for Periprosthetic Joint Infections Featured on Wien Heute, One of Austria’s Most-Watched Regional News Programs

2026-01-21T08:39:17+01:00January 7th, 2026|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on TAmiRNA Research on microRNA Biomarkers for Periprosthetic Joint Infections Featured on Wien Heute, One of Austria’s Most-Watched Regional News Programs

Research conducted by TAmiRNA in collaboration with the Michael Ogon Laboratory (Orthopädisches Spital Speising) on microRNA-based biomarkers for the early detection of periprosthetic joint infections (PJI) was recently featured on Wien Heute, one of Austria’s most widely viewed regional television news programs (ORF, January 3, 2026). The coverage highlights both the clinical relevance of the problem and the translational potential of novel molecular diagnostic approaches. Periprosthetic joint infections are among the most serious complications following hip and knee arthroplasty. Although the incidence is estimated at approximately 1-10%, PJIs are associated with substantial morbidity, prolonged treatment, and high healthcare costs. A major challenge in clinical practice remains the timely and reliable differentiation between infected and non-infected implants, particularly [...]

4 12, 2025

Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

2025-12-04T11:05:09+01:00December 4th, 2025|biomarker, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, Osteoarthritis, quality, Synovial fluid|Comments Off on Synovial Fluid and Serum microRNA Signatures in Equine Osteoarthritis

New research highlights the potential of circulating miRNAs as biomarkers for joint degeneration A new peer-reviewed study has been published in the International Journal of Molecular Sciences (IJMS): “Synovial Fluid and Serum MicroRNA Signatures in Equine Osteoarthritis.” This work provides important insights into how microRNAs (miRNAs) in serum and synovial fluid reflect the presence of osteoarthritis (OA) in horses. 🎯 Study Aim The researchers sought to identify disease-associated miRNAs that differ between healthy horses and horses with osteoarthritis. Their goal was to uncover molecular signatures that could support the development of novel biomarkers for early detection and monitoring of OA. 🔬 Methods Serum and synovial fluid samples were collected from healthy controls (n = 4) and horses [...]

26 11, 2025

TAmiRNA and Orthopaedic Hospital Speising Publish Landmark Data on promiR® for Accurate Diagnosis of Periprosthetic Joint Infections

2025-12-04T11:05:55+01:00November 26th, 2025|biomarkers in orthopaedics, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, periprosthetic joint infections, promiR, quality, Synovial fluid|Comments Off on TAmiRNA and Orthopaedic Hospital Speising Publish Landmark Data on promiR® for Accurate Diagnosis of Periprosthetic Joint Infections

On November 19th, 2025, the study “Synovial Fluid MicroRNA Biomarkers Enable Accurate Diagnosis of Hip and Knee Periprosthetic Joint Infections” by Frank et al. was published in the Journal of Bone and Joint Surgery. This peer-reviewed publication marks an important milestone in TAmiRNA’s biomarker development program and presents promiR®, our novel microRNA-based diagnostic panel designed to improve the pre-operative assessment of periprosthetic joint infections (PJIs). Clinical Challenge PJIs remain one of the most serious and difficult complications following total joint replacement. Current diagnostic methods—including inflammatory markers, imaging, and cultures—often lack sensitivity and specificity, especially for low-grade or culture-negative infections. Even advanced approaches such as PCR or next-generation sequencing can suffer from contamination risks and ambiguous [...]

11 11, 2025

Distinct microRNA profiles in human amniotic membrane its vesicular and non-vesicular secretome revealed

2025-11-11T08:44:13+01:00November 11th, 2025|exosomes, extracellular vesicle, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, quality|Comments Off on Distinct microRNA profiles in human amniotic membrane its vesicular and non-vesicular secretome revealed

Vienna, Austria – November 2025 TAmiRNA scientist have contributed significantly to a new study published by the Ludwig Boltzmann Institute for Traumatology, which is titled “Distinct miRNA profiles in human amniotic tissue and its vesicular and non-vesicular secretome”. The article was published in Frontiers in Cell and Developmental Biology on October 29th 2025. Human amniotic membrane (hAM) has been used in tissue regeneration and wound healing applications. In this study, the miND® small RNA-sequencing workflow was applied to generate fresh insights into the microRNA composition of two spatially and physiologically distinct regions of the human amniotic membrane (hAM) and its secreted extracellular vesicles (EVs) and protein-bound miRNAs. The work highlights how advanced analytical workflows can uncover tissue- [...]

21 10, 2025

TAmiRNA @ Precision Medicine EV Forum

2025-10-21T11:40:23+02:00October 21st, 2025|biomarker, Biomarker Discovery, biomarkers, congress, exosomes, extracellular vesicle, isomiR, microRNA, microRNAs, small RNA-sequencing|Comments Off on TAmiRNA @ Precision Medicine EV Forum

TAmiRNA to Exhibit at the Precision Medicine EV Forum 2025 in Cambridge Vienna, October 2025 – TAmiRNA GmbH, a leading provider of extracellular vesicle (EV) transcriptomic services, is pleased to announce its participation as an exhibitor at the Precision Medicine EV Forum 2025, taking place in Cambridge, UK, from October 27th to 28th. The forum, a key event focused on the translational aspects of EV research, provides a platform for TAmiRNA to showcase its cutting-edge solutions for biomarker discovery and therapeutic development. Meet Our Experts Our CEO/CSO, Matthias Hackl, PhD, and Scientific Consultant, Magdalena Mecking, MSc, will be on-site to meet with researchers and industry leaders. They will be available to discuss how TAmiRNA’s proprietary workflows and [...]

9 01, 2025

TAmiRNA ‘2024 In Review’

2025-01-09T14:05:02+01:00January 9th, 2025|biomarker, Biomarker Discovery, biomarkers, CE-IVD, congress, EVscale, exosomes, extracellular vesicle, hepatomiR kit, Illumina NewSeq2000, ISO 13485, liquid biopsies, Liver disease, microRNA, microRNA services, microRNAs, NGS, PCR testing service, quality, sequencing, small RNA-sequencing, smallRNA, test service|Comments Off on TAmiRNA ‘2024 In Review’

2024: A Year of Growth, Innovation, and Collaboration 2024 has come to a close. We are proud to reflect on the milestones and achievements we’ve reached together with our incredible team, customers, partners, and supporters. Here’s a look back at what we accomplished this year: 👩‍🔬 Team Expansion Welcomed 3 talented new members to our growing team. 🏥 Diagnostic Implementation Successfully rolled out our CE-IVD microRNA liver function test in 5+ clinics, advancing molecular diagnostics. ✅ Service Excellence Completed over 80 RNA service projects, achieving 100% customer satisfaction. 🛠 Bioinformatics Innovation Developed 2 new pipelines: isomiR analysis and tRNA analysis, enhancing our capabilities. 🧬 Expanded Service Offerings Added whole-transcriptome sequencing for mRNA, lncRNA, and circRNA in liquid biopsies to our service portfolio. [...]

13 02, 2024

Webinar – COST Action AtheroNET

2024-02-13T11:20:12+01:00February 13th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on Webinar – COST Action AtheroNET

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 CET Registration Link: https://lnkd.in/dVDDYKcA Reach out to Matthias directly after his webinar and discuss our latest developments and how TAmiRNA’s  miND spike ins and small RNA sequencing service can assist your business!

26 01, 2024

TAmiRNA ‘2023 In Review’

2024-01-26T11:44:38+01:00January 26th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on TAmiRNA ‘2023 In Review’

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!

Go to Top